Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2012 Aug 11;71(12):2006–2010. doi: 10.1136/annrheumdis-2012-201950

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/3.0/ and http://creativecommons.org/licenses/by-nc/3.0/legalcode

PMC Copyright notice

(A) Seroprotection rates for three influenza strains in the RA treatment groups prior to and after influenza vaccination. Horizontal bars represent levels of prevaccination protection rates for each influenza strain. *p=0.006 (TCZ vs Cont), p<0.0005 (TCZ vs MTX) and p=0.001 (TCZ vs TCZ+MTX). **p=0.007 (TCZ vs Cont, TCZ vs MTX) and p=0.023 (TCZ vs TCZ+MTX). (B) Seroresponse rates for three influenza strains in the RA treatment groups. *p=0.04 (TCZ vs MTX). **p=0.0009 (Cont vs MTX), p=0.002 (Cont vs TCZ) and p=0.022 (Cont vs TCZ+MTX). (C) Seroconversion rates for three influenza strains in the RA treatment groups. Seroconversion rates are expressed as percentages of patients with seroconversion out of seronegative patients before vaccination (antibody titres<10). *p=0.032 (TCZ vs MTX). **p=0.003 (Cont vs MTX) and p=0.002 (Cont vs TCZ+MTX). Data were compared using the χ² test or Fisher's exact probability test. Cont, RA control group; MTX, methotrexate group; RA, rheumatoid arthritis; TCZ, tocilizumab group; TCZ+MTX, combination therapy group.